TABLE 1.
Clinical characteristics of NDMM patients at baseline.
| Parameters | Total | Myc‐N | Myc‐R | Myc‐OA | p‐Value |
|---|---|---|---|---|---|
| N (%) | 417 | 299 (71.7%) | 57 (13.7%) | 61 (14.6%) | |
| Female/Male | 191/226 | 135/164 | 27/30 | 29/32 | 0.915 |
| Age (years) | 62 (54–68) | 62 (54–68.0) | 59 (54–66) | 63 (56–70) | 0.254 |
| HGB (g/L) | 95 (77–115) | 95 (76–115) | 92 (79–103) | 101 (80–119) | 0.406 |
| LDH (U/L) | 175 (142.5–222) | 175 (144–218) | 184 (129–269) | 176 (149–204) | 0.595 |
| LDH > ULN a | 66 (15.8%) | 43 (14.4%) | 16 (28.1%) | 7 (11.5%) | 0.022 |
| sCr (μmol/L) | 84.5 (66–145) | 82 (66–143) | 93 (71–215) | 82 (62.5–130.5) | 0.246 |
| Calcium (mmol/L) | 2.3 (2.16–2.48) | 2.27 (2.16–2.46) | 2.36 (2.14–2.52) | 2.34 (2.19–2.48) | 0.316 |
| Paraproteins | |||||
| IgA | 104 (24.9%) | 70 (23.4%) | 15 (26.3%) | 19 (31.1%) | 0.23 |
| IgG | 183 (43.9%) | 135 (45.2%) | 24 (42.1%) | 24 (39.3%) | |
| IgD | 27 (6.5%) | 14 (4.7%) | 8 (14.0%) | 5 (8.2%) | |
| LC | 96 (23.0%) | 74 (24.7%) | 10 (17.5%) | 12 (19.7%) | |
| Others b | 7 (1.7%) | 6 (2.0%) | 0 | 1 (0.2%) | |
| ISS | |||||
| I | 62 (15.3%) | 48 (16.4%) | 4 (7.1%) | 10 (17.2%) | 0.458 |
| II | 110 (27.1%) | 79 (27.1%) | 15 (26.8%) | 16 (27.6%) | |
| III | 234 (57.6%) | 165 (56.5%) | 37 (66.1%) | 32 (55.2%) | |
| EMD | 103 (24.7%) | 68 (22.7%) | 22 (38.6%) | 13 (21.3%) | 0.031 |
| EMD‐B/EMD‐S | 66/37 | 44/24 | 13/9 | 9/4 | 0.863 |
Note: Data are listed as n (%) and median (interquartile range, 25%–75%).
Abbreviations: EMD, extramedullary disease; EMD‐B, bone‐related EMD; EMD‐S, soft‐tissue related EMD; HGB, hemoglobin; Ig, Immunoglobulin; ISS, International Staging System; LC, light chain; LDH, lactate dehydrogenase; Myc‐N, no Myc abnormalities; Myc‐OA, other Myc abnormalities; Myc‐R, Myc rearrangement; NDMM, newly diagnosed multiple myeloma; sCr, serum creatinine; ULN, upper limit of normal value.
a
ULN = 250 U/L.
b
Other Immunoglobulin isotypes include biclonal type and nonsecretory type.